About
AFFiRiS is a clinical-stage biopharmaceutical company developing novel Specific Active Immunotherapies (SAIT) using its proprietary AFFITOME® technology to treat chronic human diseases such as neurodegenerative disorders and hypercholesterolemia.
Explore AFFiRiS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.